期刊
EUROPEAN JOURNAL OF CANCER
卷 45, 期 8, 页码 1407-1414出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2008.12.015
关键词
Lymphangiogenesis; Metastatic malignant melanoma; Vascular endothelial growth factor receptor-3 (VEGFR-3); Enzyme-linked immunosorbent assay (ELISA); Immunohistochemistry
类别
资金
- Fondation BETTENCOURT-SCHUELLER
- Caisse d'Assurance Maladie des Professions Liberales Province
- Association pour la Vie-Espoir contre le Cancer
Purpose: The presence of metastases in regional lymph nodes is a strong indicator of poor patient survival in many types of cancer. It has recently been shown that vascular endothelial growth factor-C (VEGF-C), and its receptor VEGFR-3, may play a pivotal role in the promotion of metastasis to regional lymph nodes. This study was designed to detect and evaluate whether the expression of VEGFR-3 or its soluble form plays a role in metastatic malignant melanoma and to determine the relationship with clinicopathological parameters and patients outcome. Experimental design: VEGFR-3 expression on melanoma tumour was evaluated by immunohistochemical study. Using a sensitive enzyme-linked immunosorbent assay, sVEGFR-3 was measured in sera of 60 metastatic melanoma patients in comparison with 30 healthy controls. Results: Immunohistochemical study demonstrated a high expression of VEGFR-3 in melanoma cells. Median level of pre-treatment sVEGFR-3 was significantly higher (p = 0.00001) in melanoma patients as compared to healthy donors. No association was noted between VEGFR-3 in situ or in sera and gender, age or LDH level. Median serum VEGFR-3 levels were significantly higher in patients with high tumour burden as compared to those with low tumour burden (p = 0.013) as well as in non-responding patients (n = 33) as compared to responding ones (n = 27). Finally, low level of VEGFR-3 was also related positively to disease free survival (X-2 = 3.85, p = 0.022). Conclusion: These results suggest that the expression and high pre-treatment sVEGFR-3 level are significantly correlated to poorer prognosis, and may be promising targets for new therapeutic strategies in melanoma disease. (C) 2008 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据